Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): A randomised, double-blind, parallel-group phase III trial

Annals of the Rheumatic Diseases

Volumn 76, Issue 5, 2017, Pages 840-847

  Burmester, Gerd R ^a   Lin, Yong ^b   Patel, Rahul ^b   Van Adelsberg, Janet ^c   Mangan, Erin K ^c   Graham, Neil M H ^c   Van Hoogstraten, Hubert ^b   Bauer, Deborah ^b   Ignacio Vargas, Juan ^d   Lee, Eun Bong ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SANOFI   (France)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d Quantum Research   (Chile)

^e Seoul National University   (South Korea)

Author keywords

DMARDs (biologic); Rheumatoid Arthritis; Treatment

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; SARILUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ACUTE HEART FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AORTIC DISSECTION; ARTICLE; BACTERIAL ARTHRITIS; BRONCHITIS; BURSITIS; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DEMYELINATING NEUROPATHY; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART RUPTURE; HUMAN; HYPERLIPIDEMIA; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MASTITIS; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUTROPENIA; NEUTROPHIL COUNT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ADVERSE EFFECTS; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; INJECTION; RETREATMENT; SEVERITY OF ILLNESS INDEX;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; INFECTION; INJECTIONS; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; RETREATMENT; SEVERITY OF ILLNESS INDEX;

EID: 85019144284     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210310     Document Type: Article

References (37)

1. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology(Oxford) 2012;51(Suppl 6):vi28-36.
2. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatologyguideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for themanagement of rheumatoid arthritis with synthetic and biological disease-modifyingantirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
4. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept andmethotrexate in patients with early rheumatoid arthritis. N Engl J Med2000;343:1586-93.
5. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, functionaloutcomes of treatment with adalimumab (a human anti-tumor necrosis factormonoclonal antibody) in patients with active rheumatoid arthritis receivingconcomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
6. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damagein rheumatoid arthritis patients with inadequate responses to methotrexate: Resultsfrom the double-blind treatment phase of a randomized placebo-controlled trial oftocilizumab safety and prevention of structural joint damage at one year. ArthritisRheum 2011;63:609-21.
7. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients withmethotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann InternMed 2006;144:865-76.
8. Lipsky PE, van der Heijde DM, St Clair EW, et al., for the Anti-Tumor NecrosisFactor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med2000;343:1594-602.
9. Van der Heijde D, van Adelsberg J, Fay J, et al. Clinical and radiographic outcomesafter 2 years of sarilumab in patients with rheumatoid arthritis [abstract]. AnnRheum Dis 2016;75(Suppl 2):724.
10. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use ofDMARDs on the persistence with anti-TNF therapies in patients with rheumatoidarthritis: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
11. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: Eventhough biologics are superior to conventional DMARDs overall success ratesremain low-results from RABBIT, the German biologics register. Arthritis ResTher 2006;8:R66.
12. Lee SJ, Chang H, Yazici Y, et al. Utilization trends of tumor necrosis factor inhibitorsamong patients with rheumatoid arthritis in a United States observational cohortstudy. J Rheumatol 2009;36:1611-7.
13. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumaticdrug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013;72:1897-904.
14. Backhaus M, Kaufmann J, Richter C, et al. Comparison of tocilizumab and tumournecrosis factor inhibitors in rheumatoid arthritis: A retrospective analysis of 1603patients managed in routine clinical practice. Clin Rheumatol 2015;34:673-81.
15. Pappas DA, Reed GW, Saunders K, et al. Characteristics associated with biologicmonotherapy use in biologic-naive patients with rheumatoid arthritis in a US registrypopulation. Rheumatol Ther 2015;2:85-96.
16. Detert J, Klaus P. Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics 2015;9:35-43.
17. Catay E, Bravo M, Rosa J, et al. Prevalence of biologics monotherapy in a cohort ofpatients with rheumatoid arthritis in daily clinical practice. BMC MusculoskeletDisord 2016;17:110.
18. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology ofrheumatoid arthritis. Ther Adv Musculoskelet Dis 2010;2:247-56.
19. Steiner G, Tohidast-Akrad M, Witzmann G, et al. Cytokine production bysynovial T cells in rheumatoid arthritis. Rheumatology (Oxford)1999;38:202-13.
20. Matsumoto T, Tsurumoto T, Shindo H. Interleukin-6 levels in synovial fluids ofpatients with rheumatoid arthritis correlated with the infiltration of inflammatorycells in synovial membrane. Rheumatol Int 2006;26:1096-100.
21. Sugiyama E, Kuroda A, Hori F, et al. Serum interleukin-6 level is a sensitiveparameter of disease activity in rheumatoid arthritis. J Clin Rheumatol1995;1:93-8.
22. Houssiau FA, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid andserum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
23. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: The interleukin-6receptor. Rheumatology (Oxford) 2010;49:15-24.
24. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate inpatients with active rheumatoid arthritis and inadequate response to methotrexate:results of a phase III study. Arthritis Rheumatol 2015;67:1424-37.
25. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and non-biologic diseasemodifyingantirheumatic drugs in patients with active RA and inadequate responseor intolerance to TNF inhibitors. Arthritis Rheumatol. In press.
26. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versusadalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): Arandomised, double-blind, controlled phase 4 trial. Lancet2013;381:1541-50.
27. Emery P, Rondon J, Garg A, et al. Safety and tolerability of subcutaneous sarilumaband intravenous tocilizumab in patients with RA [abstract]. Arthritis Rheumatol2015;67(Suppl 10):971.
28. Humira [package insert]. North Chicago, IL: AbbVie Inc, 2016.
29. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classificationcriteria: An American College of Rheumatology/European League AgainstRheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
30. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology1991 revised criteria for the classification of global functional status in rheumatoidarthritis. Arthritis Rheum 1992;35:498-502.
31. Gossec L, Dougados M, Rincheval N, et al. Elaboration of the preliminaryRheumatoid Arthritis Impact of Disease (RAID) score: A EULAR initiative. AnnRheum Dis 2009;68:1680-5.
32. Sanderson T, Morris M, Calnan M, et al. Patient perspective of measuring treatmentefficacy: The rheumatoid arthritis patient priorities for pharmacologic interventionsoutcomes. Arthritis Care Res (Hoboken) 2010;62:647-56.
33. Strand V, Wright GC, Bergman MJ, et al. Patient expectations and perceptions ofgoal-setting strategies for disease management in rheumatoid arthritis. J Rheumatol2015;42:2046-54.
34. Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade onneutrophil function in vitro and in vivo. Rheumatology (Oxford) 2014;53:1321-31.
35. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest2003;112:978-80.
36. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy inpatients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis2009;68:1100-4.
37. Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patientswith rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/orleflunomide. Ann Rheum Dis 2010;69:43-7.